STAT

Opinion: World leaders have the power to end TB. They must seize the moment

Ending tuberculosis, the world’s deadliest infectious disease, is doable, but by no means easy.
Patients infected with multidrug-resistant tuberculosis wait to be seen at the Doctors Without Borders HIV-AIDS clinic in Yangon, Myanmar. Globally in 2016, an estimated 600,000 people developed MDR-TB.

Attention from global leaders to ending tuberculosis, the world’s deadliest infectious disease, is growing. And that’s very good news. As we mark World TB Day and eagerly await a U.N. meeting on TB in September, we must work to sustain this commitment and build upon it to truly achieve a TB-free world.

This is doable, but by no means easy. TB claims despite being curable for the vast majority of people who contract it.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks